Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Sun Pharma and SPARC

      Sun Pharma and SPARC's XELPROS gets USFDA approval

      Medical Dialogues Bureau15 Sept 2018 4:32 PM IST
      US Food and Drug Administration (USFDA) has approved the SPARC new drug application of XELPROS, used to reduce glaucoma open-angle glaucoma or ocular...
      Ace Proxyvon Banned: Wockhardt moves Court against ban on Aceclofenac, Paracetamol, Rabeprazole Combo

      Ace Proxyvon Banned: Wockhardt moves Court against ban on Aceclofenac, Paracetamol, Rabeprazole Combo

      Medical Dialogues Bureau15 Sept 2018 1:06 PM IST
      Wockhardt is a Global pharmaceutical company that has moved the Delhi High Court against the Health Ministry's decision. Ace Proxyvon is an...
      NCLT allows Shivinder to withdraw plea against elder brother Malvinder Singh

      NCLT allows Shivinder to withdraw plea against elder brother Malvinder Singh

      Medical Dialogues Bureau15 Sept 2018 12:48 PM IST
      New Delhi: Former Fortis Healthcare promoter Shivinder Mohan Singh said that the NCLT allowed former Fortis Healthcare promoter Shivinder Mohan Singh...
      Alembic Pharma gets USFDA nod for Alogliptin and Metformin tablet

      Alembic Pharma gets USFDA nod for Alogliptin and Metformin tablet

      Medical Dialogues Bureau15 Sept 2018 12:47 PM IST
      Alogliptin and Metformin Hydrochloride tablets got tentative market approval from USFDA. It is used as the diabetes drug.New Delhi: Alembic...
      USFDA completes inspection of Nagpur facility, no observation issued: Lupin

      USFDA completes inspection of Nagpur facility, no observation issued: Lupin

      Medical Dialogues Bureau15 Sept 2018 9:41 AM IST
      New Delhi: Drug firm Lupin said the US health regulator has completed an inspection of its Nagpur facility in Maharashtra without any observation. The...
      Health Minsitry bans 328 FDC Banned Drugs, check out the complete list

      Health Minsitry bans 328 FDC Banned Drugs, check out the complete list

      Medical Dialogues Bureau14 Sept 2018 3:24 PM IST
      New Delhi: Through a recent notification, The Ministry of Health and Family Welfare has prohibited the manufacture for sale, sale or distribution for...
      FDA approves AstraZeneca drug, Lumoxiti for a type of Leukaemia

      FDA approves AstraZeneca drug, Lumoxiti for a type of Leukaemia

      Medical Dialogues Bureau14 Sept 2018 3:15 PM IST
      AstraZeneca got the green signal to treat leukaemia cancer approved by Food Drug Association (FDA). Hairy cell leukaemia is a rare form of blood...
      EU investigating second impurity in Valsartan

      EU investigating second impurity in Valsartan

      Medical Dialogues Bureau14 Sept 2018 3:05 PM IST
      FRANKFURT: Europe's drugs regulator is looking into another potentially cancer-causing substance in a common blood pressure and heart drug produced in...
      FDC Ban Welcome, will rectify GRAVE situation of pharma market: AIDAN

      FDC Ban Welcome, will rectify GRAVE situation of pharma market: AIDAN

      Medical Dialogues Bureau14 Sept 2018 2:58 PM IST
      All India Drug Action Network (AIDAN), a network of NGOs that work to increase access and improve the rational use of essential medicines, said the...
      Zydus Cadila gets USFDA nod to market Risedronate drug to treat osteoporosis

      Zydus Cadila gets USFDA nod to market Risedronate drug to treat osteoporosis

      Medical Dialogues Bureau14 Sept 2018 2:55 PM IST
      Risedronate tablets are used to treat Paget's disease of bone. Risedronate is in a class of medications called bisphosphonates. Risedronate alters...
      Shivinder to withdraw petition in NCLT against elder brother Malvinder on mothers advice

      Shivinder to withdraw petition in NCLT against elder brother Malvinder on mother's advice

      Medical Dialogues Bureau14 Sept 2018 2:01 PM IST
      New Delhi: Former Fortis Healthcare promoter Shivinder Mohan Singh said he has decided to withdraw his petition in NCLT against elder brother...
      Lets Promote Make In India: Orthopaedic Manufacturers Knock on PMs door for level playing field

      Lets Promote Make In India: Orthopaedic Manufacturers Knock on PMs door for level playing field

      Medical Dialogues Bureau13 Sept 2018 5:19 PM IST
      Government is planning to tap the trade margin at 65% In case of the orthopaedic Implant. This means that the difference in price between the first...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok